EuroACT Phase 3: Conversion – Data becomes evidence is well underway! This phase builds on the foundations of Phases 1 and 2, focusing on interpreting and iterating our findings to formulate evidence-based messages and impactful advocacy points for the patient community.

Key elements of Phase 3

1. Results interpretation

• • A critical assessment of results was conducted, synthesising research findings for each hypothesis and including a gap analysis exploring both identified gaps and their underlying causes, by our research partner Syreon.
• The EuroACT Steering Committee challenge meeting brought members together to prioritize findings, select actionable gaps, and develop aligned advocacy points.

2. Results iteration

• Focus group interviews workshops: We are conducting focus group interviews with key stakeholder groups, including:
  • Patients and patient representatives/advocates
  • HTA and PRO experts/developers
  • Pharma organisation representatives
  • Regulatory experts
    These interviews will complement the “hard facts” from our data analysis with “soft facts” about the underlying motivations of decision-makers.
• A multi-stakeholder consensus interview workshop will bring diverse perspectives together to achieve alignment on barriers and actionable recommendations.

3. Results dissemination

Phase 3 will culminate in high-impact outputs:

• Publications: Scientific manuscripts, white papers, and conference presentations will share findings broadly.

This phase represents a crucial step in translating EuroACT data into concrete, evidence-based messages for the patient community and advocacy.